A new mRNA cancer vaccine made by pharmaceutical firm Moderna is being trialled in British patients. This mRNA technology has been adapted from Covid-19 jabs and is aimed at people with advanced melanoma, lung cancer, and other solid tumour cancers. The trial is part of the British government’s partnership with Moderna to develop mRNA cancer vaccines in the UK. The technology aims to help the immune system recognize and fight cancer cells by highlighting specific protein markers on the cells of a cancerous tumour that would otherwise go undetected. This revolutionary mRNA therapy is one of two main types of cancer vaccines being developed, and it has the potential to revolutionize the way cancer is treated. The primary objective of the clinical trial is to assess the safety and tolerability of the mRNA-based therapy, as well as to evaluate its effectiveness in treating specific diseases and determine any potential side effects.